Amiodarone Toxicity Monitoring Guidelines

Initial Assessment and Baseline Testing

• A comprehensive workup for amiodarone toxicity should include targeted assessment of pulmonary, thyroid, liver, cardiac, neurologic, dermatologic, and ocular systems, with baseline and periodic monitoring of organ function through specific laboratory and diagnostic tests, as recommended by the American Academy of Family Physicians 1, 2
• Complete history and physical examination with special attention to heart failure symptoms, arrhythmia patterns, and review of all concomitant medications should be performed, according to the American Academy of Family Physicians 1, 3
• Focused assessment for symptoms of organ toxicity, including pulmonary, thyroid, liver, neurologic, dermatologic, and ocular systems, should be conducted, as suggested by the American Academy of Family Physicians 3, 4, 5

Laboratory and Diagnostic Testing

• Baseline thyroid function tests (TSH, free T4) and liver function tests (ALT, AST, bilirubin) should be obtained before starting amiodarone, as recommended by the American Academy of Family Physicians 1, 2
• Chest radiograph, pulmonary function tests with diffusing capacity (DLCO), and ophthalmologic examination should be performed at baseline, according to the American Academy of Family Physicians 1, 2
• Digoxin level and prothrombin time/INR should be monitored in patients taking digoxin or warfarin, respectively, as suggested by the American Academy of Family Physicians 1, 6

System-Specific Monitoring for Toxicity

• Pulmonary toxicity should be monitored by checking for subacute cough, progressive dyspnea, and patchy interstitial infiltrates on chest radiographs, with consideration of high-resolution CT scan for diagnosis, as recommended by the American Academy of Family Physicians 4, 7
• Thyroid dysfunction should be monitored, with consideration of thyroid hormone supplementation for hypothyroidism and withdrawal of amiodarone or addition of antithyroid medications for hyperthyroidism, according to the American Academy of Family Physicians 3, 5
• Liver toxicity should be monitored by checking for elevation of liver transaminases, with consideration of discontinuing amiodarone if liver enzyme levels exceed three times normal, as suggested by the American Academy of Family Physicians 3, 5
• Ocular effects should be monitored, with referral for ophthalmologic evaluation if visual changes occur, according to the American Academy of Family Physicians 3, 5
• Dermatologic effects should be monitored, with advice to use sunblock and cover exposed skin outdoors, as recommended by the American Academy of Family Physicians 3, 4
• Neurologic toxicity should be monitored, with consideration of dose reduction or discontinuation of amiodarone if symptoms occur, according to the American Academy of Family Physicians 3, 4
• Cardiovascular effects should be monitored, with consideration of dose adjustment or discontinuation of amiodarone if bradycardia, heart block, or QT prolongation occur, as suggested by the American Academy of Family Physicians 3, 4

Monitoring Schedule

• Thyroid function tests and liver function tests should be performed every 6 months, as recommended by the American Academy of Family Physicians 1, 2
• Directed history and physical examination for adverse effects should be performed every 6 months, according to the American Academy of Family Physicians 1, 2
• Digoxin level and prothrombin time/INR should be monitored regularly in patients taking digoxin or warfarin, respectively, as suggested by the American Academy of Family Physicians 1, 6